Results 131 to 140 of about 80,158 (218)

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

BMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang, Yuru Wang, Xuemei Li, Chaoyi Yang, Yuhui Yang, Yanyun Fang, Lin Ding, Yunlong Chen, Huangxian Ju   +8 more
wiley   +1 more source

Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting. [PDF]

Exp Hematol Oncol
Luo H, Ding Y, Zhao X.
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review. [PDF]

Front Immunol
Aureli A, Lanzilli G, Boccadamo Pompili SV, Spagnoli GC, Sconocchia G, Caratelli S.   +5 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors. [PDF]

J Immunother Cancer
Nardo G, Putti F, Indini A, Del Vecchio M, De Braud F, Di Nicola M, De Santis F.   +6 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review. [PDF]

Breast Cancer (Dove Med Press)
Abbaspour M, Esmaeil N, Akbari V, Ghoreishi M, Rafiepoor H.   +4 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

CAR-T cell therapy in non-Hodgkin lymphoma: a clinical trial landscape review. [PDF]

Front Immunol
Wu J, Liao Y, Wang W, Zhang X.
europepmc   +1 more source